After some very public cajoling, executives from some of the world’s largest drug makers have now agreed to testify about drug pricing at a Senate hearing later this month.

Of course, they would be foolish not to do so. The Senate Finance Committee leadership is not especially friendly to the pharmaceutical industry, which is already under siege. Showing up is simply smart politics in the face of proposals and legislation that could change the way they do business.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Why does Big Pharma price life saving medication like insulin, or medication older Americans take like Restasis so high? My insurance doesn’t cover these drugs needed to live, and I can’t afford them

  • Ed: All questions will be gold plated as each legislator would have deposited the necessary monies to pacify the question.

    How can Gilead rape the US based patient asking $1,000 per day when they ask patient in India about $10 per day?

    Remember what happened to Januvia (gliptin) in India. They tried to sell in the largest diabetic population country. Even the filthy rich won’t buy. They were content with Metformin. Merck finally lowered the price to make it affordable even for the rich.

  • Let me play the sage and predict that this pithy and truthful answer will not be hear, actually 2 of them.
    First, “we raise the prices because we can.”
    Second, “we set new drug prices high to avoid leaving money on the table – we can’t be expected to do that, can we?”

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy